Author

Manuel Barreiro de Acosta

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

RELATIONSHIP BETWEEN INTESTINAL ULTRASOUND, FECAL CALPROTECTIN AND HARVEY BRADSHAW INDEX IN THE ASSESSMENT OF INFLAMMATORY ACTIVITY IN CROHN'S DISEASE
RELATIONSHIP BETWEEN INTESTINAL ULTRASOUND, FECAL CALPROTECTIN AND HARVEY BRADSHAW INDEX IN THE ASSESSMENT OF INFLAMMATORY ACTIVITY IN CROHN'S DISEASE

Webinar en español | Aplicación práctica de nuevos tratamientos de la Colitis Ulcerosa
Webinar en español | Aplicación práctica de nuevos tratamientos de la Colitis Ulcerosa

Manuel Barreiro de Acosta  et al.

SEROLOGIC RESPONSE WITH ANTIMICROBIAL ANTIBODIES DURING THE PRECLINICAL PHASE OF INFLAMMATORY BOWEL DISEASE
SEROLOGIC RESPONSE WITH ANTIMICROBIAL ANTIBODIES DURING THE PRECLINICAL PHASE OF INFLAMMATORY BOWEL DISEASE

Manuel Barreiro de Acosta  et al.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

Manuel Barreiro de Acosta  et al.

The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

Manuel Barreiro de Acosta  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

Manuel Barreiro de Acosta  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Manuel Barreiro de Acosta  et al.

RELATIONSHIP BETWEEN INTESTINAL ULTRASOUND, FECAL CALPROTECTIN AND HARVEY BRADSHAW INDEX IN THE ASSESSMENT OF INFLAMMATORY ACTIVITY IN CROHN'S DISEASE
RELATIONSHIP BETWEEN INTESTINAL ULTRASOUND, FECAL CALPROTECTIN AND HARVEY BRADSHAW INDEX IN THE ASSESSMENT OF INFLAMMATORY ACTIVITY IN CROHN'S DISEASE

Manuel Barreiro de Acosta  et al.

SUBCLINICAL INFLAMMATORY BOWEL DISEASE PRECEDES THE DIAGNOSIS AND LEADS TO AN INCREASE IN HEALTHCARE RESOURCES UTILIZATION: MULTICENTER CASE-CONTROL STUDY
SUBCLINICAL INFLAMMATORY BOWEL DISEASE PRECEDES THE DIAGNOSIS AND LEADS TO AN INCREASE IN HEALTHCARE RESOURCES UTILIZATION: MULTICENTER CASE-CONTROL STUDY

Manuel Barreiro de Acosta  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

Manuel Barreiro de Acosta  et al.

BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU
BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU

Manuel Barreiro de Acosta  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Manuel Barreiro de Acosta  et al.

SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Manuel Barreiro de Acosta  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)
SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)

Manuel Barreiro de Acosta  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Manuel Barreiro de Acosta  et al.

Item 1 - 16 / 16
1